CLDN9 and coronary artery disorder: For FLT4 and CLDN9, where BH-FDR was under the 10% threshold, we evaluated the truncating ultra-rare variant burden in CHD compared to that in gnomAD: FLT4 had an even more significant association (uncorrected p-value = 2.43 × 10–15, BH-FDR = 4.01 × 10–11), whereas CLDN9 was less significant (uncorrected p-value = 7.8 × 10–4, BH-FDR = 1), leading us to question the validity of CDLN9’s association to CHD (see Supplementary Table S5 and Supplementary Figure S3).